efegatran has been researched along with Thrombosis in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (66.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bailey, DL; Bastian, JA; Briggs, SL; Chirgadze, NY; Clawson, DK; Denney, ML; Gifford-Moore, DS; Harper, RW; Johnson, LM; Klimkowski, VJ; Kohn, TJ; Lin, HS; McCowan, JR; Richett, ME; Sall, DJ; Smith, AJ; Smith, GF; Snyder, DW; Takeuchi, K; Utterback, BG; Yan, SC; Zhang, M | 1 |
| Das, J; Kimball, SD; Lau, WF; Ogletree, ML; Reid, JA; Roberts, DG; Schumacher, WA; Seiler, SM; Wang, TC | 1 |
| Chang, CY; Chong, S; Das, J; Hall, SE; Han, WC; Iwanowicz, E; Kimball, SD; Lin, J; Malley, MF; Moquin, RV; Ogletree, ML; Reid, JA; Roberts, DG; Sack, JS; Schumacher, WA; Seiler, SM; Wang-Iverson, DB | 1 |
| Bacher, P; Bajusz, S; Breddin, K; Fareed, J; Iqbal, O; Walenga, JM | 1 |
| Lucchesi, BR; Sudo, Y | 1 |
| Bagdy, D; Bajusz, S; Barabás, E; Szabó, G | 1 |
6 other study(ies) available for efegatran and Thrombosis
| Article | Year |
|---|---|
Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors: 2. Sidechain optimization and demonstration of in vivo efficacy.
Topics: Animals; Anticoagulants; Binding Sites; Crystallography, X-Ray; Disease Models, Animal; Humans; Models, Molecular; Rats; Structure-Activity Relationship; Thiophenes; Thrombin; Thrombosis | 1999 |
Thrombin active site inhibitors: chemical synthesis, in vitro and in vivo pharmacological profile of a novel and selective agent BMS-189090 and analogues.
Topics: Animals; Binding Sites; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Fibrinolytic Agents; Humans; Mice; Nipecotic Acids; Rats; Serine; Serine Proteinase Inhibitors; Structure-Activity Relationship; Substrate Specificity; Thrombin; Thrombosis | 2002 |
Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664.
Topics: Administration, Oral; Animals; Binding Sites; Crystallography, X-Ray; Dipeptides; Disease Models, Animal; Dogs; Drug Design; Drug Evaluation, Preclinical; Fibrinolytic Agents; Humans; Inhibitory Concentration 50; Macaca fascicularis; Mice; Serine Proteinase Inhibitors; Structure-Activity Relationship; Sulfonamides; Thrombin; Thrombosis | 2002 |
The antithrombotic and anticoagulant effects of a synthetic tripeptide and recombinant hirudin in various animal models.
Topics: Amino Acid Sequence; Animals; Anticoagulants; Blood Coagulation; Dose-Response Relationship, Drug; Fibrinolytic Agents; Hirudin Therapy; Hirudins; Jugular Veins; Molecular Sequence Data; Oligopeptides; Rabbits; Recombinant Proteins; Thrombosis | 1993 |
Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis: a comparison with heparin.
Topics: Animals; Anistreplase; Antithrombins; Bleeding Time; Blood Circulation; Blood Flow Velocity; Carotid Arteries; Dogs; Heparin; Jugular Veins; Male; Oligopeptides; Partial Thromboplastin Time; Thrombolytic Therapy; Thrombosis | 1996 |
Inhibition by D-MePhe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis.
Topics: Amino Acid Sequence; Animals; Anticoagulants; Arteriovenous Shunt, Surgical; Disease Models, Animal; Male; Molecular Sequence Data; Oligopeptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabbits; Rats; Thrombophlebitis; Thrombosis | 1992 |